Risk of nonmelanoma skin cancer in patients taking Janus kinase inhibitors for inflammatory bowel disease: A systematic review and meta-analysis

Background: Janus kinase (JAK) inhibitors are promising for inflammatory bowel diseases (IBDs), but their long-term safety, including risks of nonmelanoma skin cancer (NMSC), is uncertain. Objectives: The objective of the study was to conduct a systematic review and meta-analysis to examine the risk...

Повний опис

Бібліографічні деталі

Автори:	Chuen-Huei Liu, Wen-Hsuan Hou, Pi-Chu Lin, Yi-No Kang, Wei-Ting Liu, Su-Ru Chen
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Wolters Kluwer Medknow Publications 2024-09-01
Серія:	Dermatologica Sinica
Предмети:	adverse event inflammatory bowel disease janus kinase inhibitor nonmelanoma skin cancer safety
Онлайн доступ:	https://journals.lww.com/10.4103/ds.DS-D-23-00241
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!